Evidence map›Paper›PMID 26632465›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2015

[Expression and prognostic value of COX- 2, p16(INK4A) and p53 in patients with classical Hodgkin lymphoma].

Yunfei Shi, Zifen Gao, Cuiling Liu, Xin Huang, Yuqin Song, Lingyan Ping, Lixin Zhou, Min Zhao, Xiaozheng Huang, Yumei Lai and 2 more

Open access · greenAbstract read
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yunfei ShiDepartment of Pathology, Peking University, HealthScience Center. Beijing 100191, China.
Zifen GaoDepartment of Pathology, Peking University, HealthScience Center. Beijing 100191, China.
Cuiling LiuDepartment of Pathology, Peking University, HealthScience Center. Beijing 100191, China.
Xin HuangDepartment of Pathology, Peking University, HealthScience Center. Beijing 100191, China.
Yuqin SongDepartment of Pathology, Peking University, HealthScience Center. Beijing 100191, China.
Lingyan PingDepartment of Pathology, Peking University, HealthScience Center. Beijing 100191, China.
Lixin ZhouDepartment of Pathology, Peking University, HealthScience Center. Beijing 100191, China.
Min ZhaoDepartment of Pathology, Peking University, HealthScience Center. Beijing 100191, China.
Xiaozheng HuangDepartment of Pathology, Peking University, HealthScience Center. Beijing 100191, China.
Yumei LaiDepartment of Pathology, Peking University, HealthScience Center. Beijing 100191, China.
Tingting DuDepartment of Pathology, Peking University, HealthScience Center. Beijing 100191, China.
Min LiDepartment of Pathology, Peking University, HealthScience Center. Beijing 100191, China.
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the expression level of COX-2, p16(INK4A) and p53 in patients with classic Hodgkin's lymphoma (cHL), and to evaluate their correlation with prognosis.

methodsThe clinical data and samples of 52 cHL cases were collected. Immunohistochemical staining was performed to analyze the proteins level mentioned above and in situ hybridization of EBV encoded RNA (EBER) to clarify the tumor EBV infection state. Correlation between the protein expression and prognosis of patients was analyzed.

resultsOf 52 cases, the male and female ratio was 1.6∶1, the age was from 22 to 68 years old. All lesions located primarily in lymph nodes. All samples from 52 cases were stained with COX-2, p16(INK4A) and p53, and the positive expression of COX-2 was found in 28 cases (53.8%), that of p16(INK4A) in 25 cases (48.1%)and p53 in 42 cases (80.8%). All patients were divided into two groups according to differences in age (<40 years/ ≥ 40 years), gender (male/female), EBV infection (yes/no), B symptoms (yes/no), and the Ann Arbor staging (Ⅰ-Ⅱ/Ⅲ-Ⅳ), the correlation with COX-2, p16(INK4A) and p53 expression were analyzed, and only p53 expression was correlated with Ann Arbor staging (P=0.027). The statistical analysis of correlations between COX- 2, p16(INK4A) and p53 showed that the expression of COX-2 was strongly correlated with p53 (P=0.008), and p16 (INK4A) was not related to either COX-2 or p53 (P=0.246 and 0.958). Kaplan- Meier univariate OS analysis using SPSS17.0 software showed that only COX-2 expression was an adverse prognostic factor for patients'event free survival (EFS) (P=0.003). Meanwhile COX-2 expression was a unique independent prognostic factor analyzed by COX proportional hazards regression model (HR=0.091, 95% CI 0.017-0.505, P=0.006).

conclusionThe expression rate of COX-2, p16 (INK4A) and p53 in the cHL were relatively high; and they were not statistically correlated with tumor EBV infection status; the COX-2 positive group had poor prognosis, but only event free survival time becomes statistically significant shorter. COX proportional hazard regression model was used to analyze the COX-2 expression as a independent adverse prognostic factors for EFS.

Indexed as

AdultAgedCyclin-Dependent Kinase Inhibitor p16Cyclooxygenase 2Disease-Free SurvivalEpstein-Barr Virus InfectionsFemaleHodgkin DiseaseHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedPrognosisProportional Hazards ModelsTumor Suppressor Protein p53Cyclin-Dependent Kinase Inhibitor p16Cyclooxygenase 2PTGS2 protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID26632465
PMCPMC7342425
OpenAlexW2183861264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.